论文部分内容阅读
目的观察甲地孕酮对晚期大肠癌的辅助治疗作用。方法80例大肠癌通过双盲法,分为试验组40例(化疗+甲地孕酮)和对照组40例(化疗+安慰剂)。结果与对照组相比,试验组患者的近期有效率、TTP、中位生存期和1年生存率分别为55.0%、10个月、23个月和95.0%,均明显高于对照组20.0%、5.9个月、13个月和50.0%,且差异有显著性(P<0.05);毒副作用也较对照组轻。结论甲地孕酮辅助化疗对大肠癌患者具有一定的增效减毒作用。
Objective To observe the adjuvant therapy of megestrol on advanced colorectal cancer. Methods 80 cases of colorectal cancer were divided into experimental group 40 cases (chemotherapy + megestrol) and control group 40 cases (chemotherapy + placebo) by double-blind method. Results Compared with the control group, the short-term effective rate, the TTP, the median survival time and the 1-year survival rate were 55.0%, 10 months, 23 months and 95.0% in the test group, which were significantly higher than those in the control group (20.0% , 5.9 months, 13 months and 50.0%, respectively, with significant difference (P <0.05). The toxic side effects were also lighter than those in the control group. Conclusions Medroxyprogesterone acetate adjuvant chemotherapy has a synergistic and attenuating effect on patients with colorectal cancer.